Steady royalties, upcoming results

Bioventix (LSE:BVXP) is due to report results for the year to 30 June 2026. Its most recent trading statement came with the interim results on 30 March 2026, when the company said trading was in line with expectations for the full year. Since then, its announcements have mainly covered director dealings, share option awards and holdings notifications, with the latest director dealing on 24 June 2026.

What the company does

Bioventix develops and supplies high-affinity sheep monoclonal antibodies used in blood-testing diagnostics. Large diagnostics companies build these antibodies into their automated immunoassays, and Bioventix earns most of its income from royalties on the sale of those tests worldwide. Its long-established products include antibodies used in vitamin D and troponin tests. It is also developing antibodies for neurology biomarkers. The model is capital-light. Bioventix does not manufacture finished tests itself. It relies on partners to obtain regulatory approvals and sell analysers and reagents to hospitals and laboratories, and royalties typically flow for many years once an antibody is designed into a commercial assay.

Latest developments

In the half-year to 31 December 2025, revenue was £6.16 million, compared with £6.73 million a year earlier. Pre-tax profit was £4.85 million, down from £5.05 million. On a constant-currency basis, revenue would have been about £6.4 million. The company described troponin sales as steady. It noted that Siemens obtained a US FDA label extension in November 2024 but that no resulting royalty uplift had yet appeared. Royalties from tau and other neurology antibodies rose fivefold to about £150,000. All of that income came from assays labelled for laboratory use only, and Bioventix said its antibodies feature in several leading blood-based pT217 and total tau assay designs. It also mentioned work with the University of Gothenburg on a tau tangle biomarker.

Financial and dividend picture

Bioventix is known for paying out a large share of its earnings. It declared an unchanged interim dividend of 70p per share, paid on 24 April 2026. Cash at 31 December 2025 was £5.3 million, slightly above the £5.1 million held a year earlier, underlining the cash-generative nature of the model. On 12 October 2026, the shares stood at around 1,810p, valuing the company at roughly £95 million.

Sector and index context

Within the FTSE AIM All Share Index, Bioventix is unusual: a small, highly profitable healthcare business with a long dividend record. The in vitro diagnostics sector has been affected by weaker demand in China and by pricing pressure. At the same time, blood tests for Alzheimer's disease are attracting growing attention from diagnostics companies.

Key risks

The company depends heavily on a handful of large diagnostics partners and on royalties paid in foreign currencies. Sterling strength therefore reduces reported revenue. Older products are maturing, and management has itself said that the timing of regulatory approvals for new in vitro diagnostic products is difficult to predict.

What to watch next

The full-year results should give the final dividend declaration, an update on whether troponin royalties are rising after the Siemens label extension, and progress on neurology antibodies, including any move from laboratory-use-only to clinical assays. Any commentary on demand in China, which has weighed on some diagnostics businesses, would also be relevant. Investors will also look for comments on currency effects and on whether the company still expects its cash position to keep supporting its distribution policy.